MLchartDataset catalogue

Synribo

Term · Oncology and biomedicine · MLC-T-ONC-008451

A drug used to treat adults with certain types of chronic myelogenous leukemia that cannot be treated with tyrosine kinase inhibitors (a type of anticancer drug) or that have not gotten better after treatment with at least two tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Synribo blocks certain proteins involved in cell growth and may kill cancer cells. It is a type of plant alkaloid and a type of protein synthesis inhibitor. Also called homoharringtonine and omacetaxine mepesuccinate.

Table 1. Record
IdentifierMLC-T-ONC-008451
FieldOncology and biomedicine
Synonymshomoharringtonine; omacetaxine mepesuccinate
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-008451",
  "term": "Synribo",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults with certain types of chronic myelogenous leukemia that cannot be treated with tyrosine kinase inhibitors (a type of anticancer drug) or that have not gotten better after treatment with at least two tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Synribo blocks certain proteins involved in cell growth and may kill cancer cells. It is a type of plant alkaloid and a type of protein synthesis inhibitor. Also called homoharringtonine and omacetaxine mepesuccinate.",
  "synonyms": [
    "homoharringtonine",
    "omacetaxine mepesuccinate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/synribo/"
}

Record 15,873 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.